These findings suggest that SMARCA4 may have a similar effect on the prognosis of both NSCLC and thoracic SMARCA4‐UT, providing insights for future implications in prognosis and treatment strategies for SMARCA4‐deficient tumors. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.